Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy
Abstract Angiotensin‐converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure‐independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of ACEi on anti‐fibrotic biomarkers in Afric...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-05-01
|
| Series: | The Journal of Clinical Hypertension |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jch.14206 |
| _version_ | 1827778897321656320 |
|---|---|
| author | Cesar A.Romero Shobi Mathew Benjamin Wasinski Brian Reed Aaron Brody Rachelle Dawood Michael J. Twiner Candace D. McNaughton Rafael Fridman John M. Flack Oscar A. Carretero Phillip D. Levy |
| author_facet | Cesar A.Romero Shobi Mathew Benjamin Wasinski Brian Reed Aaron Brody Rachelle Dawood Michael J. Twiner Candace D. McNaughton Rafael Fridman John M. Flack Oscar A. Carretero Phillip D. Levy |
| author_sort | Cesar A.Romero |
| collection | DOAJ |
| description | Abstract Angiotensin‐converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure‐independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of ACEi on anti‐fibrotic biomarkers in African American hypertensive patients with left ventricular hypertrophy (LVH). We conducted a post hoc analysis of a randomized controlled trial in which hypertensive African American patients with LVH and vitamin D deficiency were randomized to receive intensive antihypertensive therapy plus vitamin D supplementation or placebo. We selected patients who had detectable lisinopril (lisinopril group) in plasma using liquid‐chromatography/mass spectrometry analysis and compared them to subjects who did not (comparison group) at the one‐year follow‐up. The pro‐fibrotic marker type 1 procollagen C‐terminal propeptide (PICP) and the anti‐fibrotic markers matrix metalloproteinase‐1 (MMP‐1), tissue inhibitor of metalloproteinases 1 (TIMP‐1), telopeptide of collagen type I (CITP), and N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (Ac‐SDKP) peptide were measured. Sixty‐six patients were included, and the mean age was 46.2 ± 8 years. No difference was observed in the number and intensity of antihypertensive medications prescribed in each group. Patients with detectable lisinopril had lower blood pressure than those in the comparison group. The anti‐fibrotic markers Ac‐SDKP, MMP‐1, and MMP‐1/TIMP‐1 ratio were higher in patients with detectable ACEi (all p < .05). In a model adjusted for systolic blood pressure, MMP‐1/TIMP‐1 (p = .02) and Ac‐SDKP (p < .001) levels were associated with lisinopril. We conclude that ACEi increase anti‐fibrotic biomarkers in hypertensive African Americans with LVH, suggesting that they may offer added benefit over other agents in such patients. |
| first_indexed | 2024-03-11T14:42:35Z |
| format | Article |
| id | doaj.art-9e2ff4d99bdc4f658ac0a41ad2fa6f0f |
| institution | Directory Open Access Journal |
| issn | 1524-6175 1751-7176 |
| language | English |
| last_indexed | 2024-03-11T14:42:35Z |
| publishDate | 2021-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Journal of Clinical Hypertension |
| spelling | doaj.art-9e2ff4d99bdc4f658ac0a41ad2fa6f0f2023-10-30T13:30:30ZengWileyThe Journal of Clinical Hypertension1524-61751751-71762021-05-012351008101610.1111/jch.14206Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophyCesar A.Romero0Shobi Mathew1Benjamin Wasinski2Brian Reed3Aaron Brody4Rachelle Dawood5Michael J. Twiner6Candace D. McNaughton7Rafael Fridman8John M. Flack9Oscar A. Carretero10Phillip D. Levy11Hypertension and Vascular Research Division Internal Medicine Department Henry Ford Hospital Detroit MI USADepartment of Emergency Medicine and Integrative Biosciences Center Wayne State University Detroit MI USADepartment of Emergency Medicine and Integrative Biosciences Center Wayne State University Detroit MI USADepartment of Emergency Medicine and Integrative Biosciences Center Wayne State University Detroit MI USADepartment of Emergency Medicine and Integrative Biosciences Center Wayne State University Detroit MI USADepartment of Emergency Medicine and Integrative Biosciences Center Wayne State University Detroit MI USADepartment of Emergency Medicine and Integrative Biosciences Center Wayne State University Detroit MI USADepartment of Emergency Medicine Vanderbilt University Medical Center and Geriatric Research Education Clinical Center VA Medical Center Nashville TN USADepartment of Pathology and Oncology Wayne State University Detroit MI USASchool of Medicine Department of Internal Medicine Southern Illinois University Springfield IL USAHypertension and Vascular Research Division Internal Medicine Department Henry Ford Hospital Detroit MI USADepartment of Emergency Medicine and Integrative Biosciences Center Wayne State University Detroit MI USAAbstract Angiotensin‐converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure‐independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of ACEi on anti‐fibrotic biomarkers in African American hypertensive patients with left ventricular hypertrophy (LVH). We conducted a post hoc analysis of a randomized controlled trial in which hypertensive African American patients with LVH and vitamin D deficiency were randomized to receive intensive antihypertensive therapy plus vitamin D supplementation or placebo. We selected patients who had detectable lisinopril (lisinopril group) in plasma using liquid‐chromatography/mass spectrometry analysis and compared them to subjects who did not (comparison group) at the one‐year follow‐up. The pro‐fibrotic marker type 1 procollagen C‐terminal propeptide (PICP) and the anti‐fibrotic markers matrix metalloproteinase‐1 (MMP‐1), tissue inhibitor of metalloproteinases 1 (TIMP‐1), telopeptide of collagen type I (CITP), and N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (Ac‐SDKP) peptide were measured. Sixty‐six patients were included, and the mean age was 46.2 ± 8 years. No difference was observed in the number and intensity of antihypertensive medications prescribed in each group. Patients with detectable lisinopril had lower blood pressure than those in the comparison group. The anti‐fibrotic markers Ac‐SDKP, MMP‐1, and MMP‐1/TIMP‐1 ratio were higher in patients with detectable ACEi (all p < .05). In a model adjusted for systolic blood pressure, MMP‐1/TIMP‐1 (p = .02) and Ac‐SDKP (p < .001) levels were associated with lisinopril. We conclude that ACEi increase anti‐fibrotic biomarkers in hypertensive African Americans with LVH, suggesting that they may offer added benefit over other agents in such patients.https://doi.org/10.1111/jch.14206ACE inhibitorsAc‐SDKPAfrican Americancollagenleft ventricular hypertrophyMMP‐1 |
| spellingShingle | Cesar A.Romero Shobi Mathew Benjamin Wasinski Brian Reed Aaron Brody Rachelle Dawood Michael J. Twiner Candace D. McNaughton Rafael Fridman John M. Flack Oscar A. Carretero Phillip D. Levy Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy The Journal of Clinical Hypertension ACE inhibitors Ac‐SDKP African American collagen left ventricular hypertrophy MMP‐1 |
| title | Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy |
| title_full | Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy |
| title_fullStr | Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy |
| title_full_unstemmed | Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy |
| title_short | Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy |
| title_sort | angiotensin converting enzyme inhibitors increase anti fibrotic biomarkers in african americans with left ventricular hypertrophy |
| topic | ACE inhibitors Ac‐SDKP African American collagen left ventricular hypertrophy MMP‐1 |
| url | https://doi.org/10.1111/jch.14206 |
| work_keys_str_mv | AT cesararomero angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT shobimathew angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT benjaminwasinski angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT brianreed angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT aaronbrody angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT rachelledawood angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT michaeljtwiner angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT candacedmcnaughton angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT rafaelfridman angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT johnmflack angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT oscaracarretero angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy AT phillipdlevy angiotensinconvertingenzymeinhibitorsincreaseantifibroticbiomarkersinafricanamericanswithleftventricularhypertrophy |